Nephrol Dial Transplant (2002) 17: 2077-2080
© 2002 European Renal Association-European Dialysis and Transplant Association
Controversy
Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis
Department of Nephrology, University Medical Centre Groningen, Groningen, The Netherlands
Keywords: ANCA; microscopic polyangiitis; myeloperoxidase; proteinase-3; small-vessel vasculitis; Wegener's granulomatosis
| The first 150 words of the full text of this article appear below. |
Since the discovery of the link between anti-neutrophil cytoplasmic antibodies (ANCA) directed against proteinase-3 (PR3) and myeloperoxidase (MPO) and small-vessel vasculitis, the diagnostic potential of these antibodies has been appreciated [1,2]. High sensitivity and specificity of validated antigen-specific tests for Wegener's granulomatosis (WG), microscopic polyangiitis (MPA) and the renal limited form of small-vessel vasculitis, pauci-immune necrotizing glomerulonephritis (renal limited vasculitis; RLV), have been demonstrated [3]. It should be stressed that it is essential to use antigen-specific tests such as ELISA with purified antigen in addition to the screening by indirect immunofluorescence (IIF) on ethanol-fixed neutrophils as the finding of a diffuse cytoplasmic (C-ANCA) or peri-nuclear fluorescence pattern (P-ANCA) is not equivalent to the presence of antibodies directed against PR3 and MPO, respectively (Table 1
). Especially the finding of P-ANCA lacks specificity as these can be found in many other conditions.
|
Does ANCA specificity have prognostic value?
Do ANCA levels during initial immunosuppressive treatment predict treatment failure or relapse?
Do changes in ANCA level during follow up adequately predict relapse?
Can the relation between ANCA levels and vasculitic disease activity be improved?
Conclusions
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B Terrier, D Saadoun, D Sene, P Ghillani, Z Amoura, G Deray, B Fautrel, J-C Piette, and P Cacoub Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides Ann Rheum Dis, October 1, 2009; 68(10): 1564 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Agarwal, J Harper, and P. Kiely Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus Lupus, April 1, 2009; 18(5): 407 - 412. [Abstract] [PDF]
|
|
|
|
 |
|
 J. D. Finkielman, P. A. Merkel, D. Schroeder, G. S. Hoffman, R. Spiera, E. W. St. Clair, J. C. Davis Jr., W. J. McCune, A. K. Lears, S. R. Ytterberg, et al. Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis Ann Intern Med, November 6, 2007; 147(9): 611 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J-S F Sanders, M G Huitma, C G M Kallenberg, and C A Stegeman Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse Ann Rheum Dis, November 1, 2006; 65(11): 1484 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. F. Sanders, M. G. Huitma, C. G. M. Kallenberg, and C. A. Stegeman Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment Rheumatology, June 1, 2006; 45(6): 724 - 729. [Abstract] [Full Text] [PDF]
|
|